An exceptionally bright future on path to becoming ...Theralase® has an exceptionally bright future and we look forward to having Roger lead us on the path to becoming a commercial-stage pharmaceutical company. Apart from a news release from the FDA confirming the granting of a Brealthrough Theraphy desingation, it cannot get closer than that.
They sound like they are extremely confident. This, right after the Dr. Kulkarni\Dr. Kamat interview, also sounds like their communications with the FDA has led them to conclude that we will succeed.
So I think it's fair to assume that it's a strong signal/milestone that Breakthrough Therapy application has now been submitted and that a positive response from the FDA leaves no doubt. The FDA would now have 60 days to reply.
I also think that it's fair to assume that we might hear a bit more about their plans regarding Rutherrin (NSCLC, Glioblastoma) in a nearby future, most probably after the granting of the FDA Breakthrough Therapy designation, in order to gain maximum visibility.
Theralase® has an exceptionally bright future and we look forward to having Roger lead us on the path to becoming a commercial-stage pharmaceutical company.